US Legislation Targets Offshoring of Biotech Industry to China Amid Rising Tensions
Severity: High (Score: 60.0)
Sources: Scmp, Chinaselectcommittee.House
Published: · Updated:
Keywords: biotech, china, moolenaar, dingell, legislation, industry, next
Severity indicators: ot
Summary
On June 2, 2026, US lawmakers introduced the Biotech Investment National Security Act (BINSA) to prevent offshoring of the biotech industry to China. This legislation mandates that American investments in Chinese biotech firms undergo scrutiny under the Comprehensive Outbound Investment National Security (COINS) Act. The act aims to protect US pharmaceutical production and innovation, as American companies like Pfizer engage in significant licensing deals with Chinese firms. In the first quarter of 2026, Chinese biotech companies secured a record $60 billion in cross-border licensing deals, raising alarms in Washington about dependency on Chinese supply chains. Congressman John Moolenaar emphasized that US capital flowing to Chinese biotech aids China's pharmaceutical strategy and threatens US national security. The legislation seeks to ensure that US investments do not inadvertently bolster Chinese biotech capabilities that could undermine American interests. Key Points: • The Biotech Investment National Security Act was introduced to prevent US biotech offshoring to China. • Chinese biotech firms secured $60 billion in cross-border deals in Q1 2026, raising US concerns. • US investments in Chinese biotech will now be subject to scrutiny under the COINS Act.
Detailed Analysis
**Impact** U.S. biotechnology and pharmaceutical sectors are affected by increased offshoring of investment, technology, and expertise to Chinese biotech companies. Cross-border licensing deals grew from under $5 billion in 2020 to approximately $136 billion in 2025, with Chinese firms accounting for 69% of global biotech deal value in Q1 2026. This shift risks hollowing out U.S. research infrastructure, undermining domestic pharmaceutical production, and increasing dependency on Chinese supply chains. Key affected sectors include pharmaceutical development, biologics manufacturing, and clinical R&D, primarily in the United States and China. **Technical Details** The event involves outbound investment and technology transfer through licensing agreements, joint ventures, and equity investments rather than cyberattack vectors or malware. No specific cyber intrusion techniques, CVEs, or malware tools are mentioned. The transfer of drug discovery platforms and biologics manufacturing know-how to Chinese entities under CCP control constitutes the primary mechanism of concern. No IOCs or infrastructure details are provided. **Recommended Response** Implement regulatory scrutiny on outbound investments in biotechnology, including licensing deals and joint ventures with Chinese entities, as mandated by the Biotech Investment National Security Act (BINSA). Monitor and review all pharmaceutical-related technology transfers and equity investments for national security risks. Coordinate with Treasury, HHS, DOD, and intelligence agencies to assess and mitigate risks from capital flows. No specific cybersecurity detection or patching actions are indicated; focus should be on compliance monitoring and investment screening.
Source articles (2)
- Moolenaar, Dingell Introduce Legislation to Prevent Offshoring Biotech Industry to China — Chinaselectcommittee.House · 2026-06-02
Today, Chairman John Moolenaar (R-MI) of the Select Committee on China and Congresswoman Debbie Dingell (D-MI) introduced the Biotech Investment National Security Act (BINSA). This legislation would e… - The next tech war? Why biotech may become a new US — Scmp · 2026-06-03
China’s biotech industry is rapidly moving up the value chain, prompting fears in the US and calls for tighter controls The wide-ranging geopolitical rivalry between Beijing and Washington could soon…
Timeline
- 2026-05-21 — Moolenaar's letter to Treasury Secretary: Congressman Moolenaar warned that US capital flowing to Chinese biotech aids China's strategy and threatens US security.
- 2026-06-02 — Introduction of the Biotech Investment National Security Act: Lawmakers introduced BINSA to prevent offshoring of biotech investments to China, enhancing scrutiny on US investments.
- 2026-06-03 — Chinese biotech firms secure record licensing deals: Chinese companies struck $60 billion in cross-border licensing deals in Q1 2026, accounting for 69% of global biotech deal-making.
Related entities
- China (Country)
- United States (Country)
- Manufacturing (Industry)
- Technology (Industry)